Article citationsMore>>
Foster, G.R., Irving, W.L., Cheung, M.C., Walker, A.J., Hudson, B.E., Verma, S., McLauchlan, J., Mutimer, D.J., Brown, A., Gelson, W.T., et al. (2016) Impact of Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C and Decompensated Cirrhosis. Journal of Hepatology, 64, 1224-1231.
https://doi.org/10.1016/j.jhep.2016.01.029
has been cited by the following article:
-
TITLE:
Value of Child-Turcotte-Pugh Score in Prediction of Treatment Response in “Difficult to Treat” Chronic HCV Cirrhotic Patients
AUTHORS:
Taghrid Mohamed Abdalla, Sameh M. Abdel Monem, Hosam M. Dawod
KEYWORDS:
Hepatitis C, Child Score, Cirrhosis
JOURNAL NAME:
Open Journal of Gastroenterology,
Vol.9 No.11,
November
21,
2019
ABSTRACT: Background and aim: The direct-acting antivirals (DAAs) treatment has greatly improved sustained virologic response (SVR) in chronic non-cirrhotic hepatitis C virus (HCV) patients and to less extent in those with cirrhosis. There is a stressing need for predicting the outcome of DAAs treatment especially in “difficult to treat” patients. This work aimed to study the value of the Child-Turcotte-Pugh (CTP) score in the prediction of treatment outcome with DAAs in “difficult to treat” chronic HCV patients. Materials and methods: A retrospective cohort study was conducted where files of 120 “difficult to treat” patients were randomly selected from the follow-up clinic. Patients’ data were collected before and after treatment including history taking, clinical examination, laboratory investigations, and abdominal ultrasonography. Child-Turcotte-Pugh (CTP) scores were calculated. Results: There was no significant difference in mean Child score between patients with and without SVR before treatment, while this difference became significant after treatment. The patients without complications showed a highly significant decrease in their mean Child score after treatment, while patients with complications did not show any significant differences. Conclusion: The baseline Child-Turcotte-Pugh score cannot predict the treatment response of DAAs in “difficult to treat” chronic HCV patients, but it is significantly associated with the occurrence of complications.
Related Articles:
-
Laté Mawuli Lawson-Ananissoh, Aklesso Bagny, Oumboma Bouglouga, Laconi Kaaga, Rafiou El-Hadji Yakoubou, Lidaw Kogoe, Datouda Redah
-
Hakima Abid, Maryam Khayari, Hajar Cherkaoui, Maria Lahlali, Nada Lahmidani, Mounia Elyousfi, Nourdin Aqodad, Sidi Adil Ibrahimi, Mohamed El Abkari
-
P. Patrick Basu, Robert S. Brown Jr.
-
Gilmar Amorim de Sousa, Iris do Céu Clara Costa, Dyego Leandro Bezerra de Souza, Fabia Barbosa de Andrade, Lívia Medeiros Soares Celani, Ranna Santos Pessoa, Marlon César de Souza Filho, Daniel Fernandes Mello de Oliveira, Luana Lopes de Medeiros, Lucila Samara Dantas de Oliveira, Maria Flávia Monteiro
-
Noboru Hirashima, Masaaki Shimada, Noboru Urata, Takuya Tsunekawa, Satoshi Unita, Takashi Kondo, Daiki Tanaka, Hisashi Kondo, Masashi Saito, Hiroaki Iwase